Advances in amyloidosis
1 September from 17:00 to 18:00
Science Box 1 - Research Gateway
Abstract Sessions
ecg_heart Pharmacotherapy
Presentations
17:00 Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: a nationwide retrospective study using a medical claims database Presenter: Hajime Abe (Japan) View abstract
17:12 Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline Presenter: Marianna Fontana (University College London - London, United Kingdom of Great Britain & Northern Ireland) View abstract
17:24 Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center. Presenter: Rita Carvalho (Western Lisbon Hospital Centre, EPE - Lisbon, Portugal) View abstract
17:36 Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE Presenter: Olivier Lairez (University Hospital of Toulouse - Toulouse, France) 
lairez View abstract
lairez View abstract 17:48 Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101 Presenter: Peter Van Der Meer (University Medical Centre Groningen - Groningen, Netherlands (The)) p_van_der_meer View abstract
p_van_der_meer View abstract 